PRELIMINARY RESULTS OF THE EARLY USE OF CORTICOSTEROIDS WITH AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS DIAGNOSED WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)

被引：0
|
作者：
Max, Topp S. [1 ]
Van Meerten, T. [2 ]
Wermke, M.
Pieternella, Lugtenburg J. [3 ]
Monique, Minnema C. [4 ]
Kevin, Song W. [5 ]
Thieblemont, C.
Jiang, Y. [6 ]
Plaks, V [7 ]
Kerber, A. [8 ]
Kersten, M. J. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Hosp Carl Gustav Carus, Dresden, Germany
[4] Erasmus MC, Lunenburg Lymphoma Phase 1 2 Consortium HOVON LLP, Rotterdam, Netherlands
[5] Univ Med Ctr Utrecht, Utrecht, Netherlands
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Hop St Louis, Paris, France
[8] Kite, Santa Monica, CA USA
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-132
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [31] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Chaganti, Sridhar
    Cwynarski, Kate
    Cunningham, David
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Radford, John
    Westin, Jason R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
  • [32] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy S.
    Kamdar, Manali
    Liu, Fei Fei
    Crotta, Alessandro
    Previtali, Alessandro
    Klijn, Sven L.
    Wang, Pearl
    Situ, Aaron
    Zhang, Yixie
    Bonner, Ashley
    Lunning, Matthew A.
    BLOOD, 2022, 140 : 4655 - 4656
  • [33] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
    Oluwole, Olalekan O.
    Forcade, Edouard
    Muñoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John M.
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Kim, Jenny J.
    Zheng, Yan
    Shen, Rhine R.
    Vardhanabhuti, Saran
    Van Meerten, Tom
    BLOOD, 2021, 138
  • [34] Matching- adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
    Oluwole, O. O.
    Ray, M. D.
    Chen, J. M.
    Chan, K.
    Zhang, I.
    Keeping, S.
    Smith, H.
    Spooner, C. L. Bellasis
    Patel, A. R.
    Locke, F. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S548 - S548
  • [35] Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and glofitamab (glofit) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
    Locke, F. L.
    Chen, J. M.
    Chan, K.
    Ray, M. D.
    Zhang, I.
    Keeping, S.
    Fu, C.
    Patel, A. R.
    Oluwole, O. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S549 - S549
  • [36] Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Vose, Julie M.
    Lin, Yi
    Budde, Lihua E.
    Maloney, David G.
    Jaglowski, Samantha
    Riedell, Peter A.
    Lekakis, Lazaros J.
    Perales, Miguel-Angel
    Kim, Jenny J.
    Kawashima, Jun
    Yang, Yin
    Rossi, John M.
    Goyal, Lovely
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [37] Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed B-Cell Lymphoma Receiving Axicabtagene Ciloleucel (Axi-cel)
    Mian, Agrima
    Wei, Wei
    Hill, Brian T.
    Hamilton, Betty K.
    Pohlman, Brad
    Jagadeesh, Deepa
    Anwer, Faiz
    Kalaycio, Matt E.
    Dean, Robert M.
    Sobecks, Ronald M.
    Majhail, Navneet S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S44 - S45
  • [38] Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Dreger, P.
    Westin, J.
    Oluwole, O.
    Kersten, M. J.
    Miklos, D.
    Perales, M. -A
    Ghobadi, A.
    Rapoport, A.
    Sureda, A.
    Jacobson, C.
    Farooq, U.
    van Meerten, T.
    Ulrickson, M.
    Elsawy, M.
    Leslie, L.
    Chaganti, S.
    Dickinson, M.
    Yang, Y.
    Schupp, M.
    To, C.
    Locke, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 271 - 272
  • [39] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axicel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/ R LBCL): A Multicenter Analysis
    Vuyyala, Sowjanya
    Corraes, Andre De Menezes Silva
    Bailey, Megumi
    Iqbal, Madiha
    Munoz, Javier L.
    Hunter, Bradley
    Bansal, Radhika
    Patel, Krish
    Kharfan-Dabaja, Mohamed A.
    Rosenthal, Allison C.
    Wang, Yucai
    Paludo, Jonas
    Johnston, Patrick B.
    Bennani, N. Nora
    Villasboas, J. C. C.
    Durani, Urshila
    Ansell, Stephen M.
    Lin, Yi
    Khurana, Arushi
    BLOOD, 2023, 142
12345